Reply To: Adjuvant targeted therapy

[Mollie Reed]

I also agree with you all. I think that providers will start with IO unless it is contraindicated (pre-existing autoimmune disease, etc.). Plus, we all know how horribly the disease “explodes” once resistant to BRAF therapy. It will be interesting to see how it plays out, though.